From pig kidney transplants to the development of a new schizophrenia drug, here are five of the biggest medical ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that ...

P rogress in addressing mental health is notoriously slow and mostly incremental. Breakthrough treatments tend to be rare, ...

BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely ...

A groundbreaking antipsychotic, a powerful new antibiotic, and a vaccine-like prophylactic for HIV are some of the most ...

Bristol Myers Squibb’s Cobenfy is the first treatment in seven decades that does not modulate dopaminergic or serotonergic ...

There are always new frontiers in health care: diseases whose treatment and cures still elude us; biological and medical ...

On 26 September 2024, Cobenfy (KarXT) gained US Food and Drug Administration (FDA) approval as the first novel class of antipsychotics in decades. Developed by Karuna Therapeutics, recently ...

According to GlobalData’s Drugs Database, the schizophrenia market remains dominated by dopamine-targeted mechanisms, such as ...

BMY)’s shares gained 8% over the next couple of days in September after the FDA approved the drug. Cramer is also optimistic about Cobenfy as he shared: “We pulled the trigger for the ...

In September this year, the FDA approved Bristol Myers Squibb’s Cobenfy for schizophrenia. Reportedly, this is the first truly novel drug for schizophrenia seen since the 1950s. In clinical ...